Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/29933
Full metadata record
DC FieldValueLanguage
dc.contributor.authorUmapathysivam, Mahesh-
dc.contributor.authorGrossmann, Mathis-
dc.contributor.authorWittert, Gary A-
dc.date2022-
dc.date.accessioned2022-06-22T06:40:50Z-
dc.date.available2022-06-22T06:40:50Z-
dc.date.issued2022-03-31-
dc.identifier.citationBest Practice & Research. Clinical Endocrinology & Metabolism 2022; 36(5): 101654en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/29933-
dc.description.abstractType 2 diabetes (T2D) and obesity are common and associated with increased morbidity and mortality. Cross-sectional and longitudinal studies have demonstrated a clear association between T2D, obesity and reduced total testosterone concentration. This relationship becomes less significant or absent with correction for changes in body composition, supporting the notion that changes in body composition are mediating these effects. Moreover, this mediating effect of body composition changes is bi-directional, as evidenced by interventional studies of weight loss and testosterone treatment. On the one hand, in obese men, serum testosterone increases markedly with weight loss. On the other hand, testosterone improves body composition. This relationship is driven by multiple complex interaction between obesity and insulin resistance and the hypothalamic-pituitary-testicular axis, at all levels. Data from randomised control trials have demonstrated that intervention with testosterone therapy increases muscle mass and reduces adiposity. Most recently it has been shown that treatment with testosterone prevents progression of impaired glucose tolerance to T2D, or reverses newly diagnosed T2D beyond lifestyle intervention alone. At present there are insufficient safety data to support the use of testosterone for prevention of type 2 diabetes.en_US
dc.language.isoeng-
dc.subjectandrogenen_US
dc.subjectdiabetesen_US
dc.subjectglucoseen_US
dc.subjectmetabolismen_US
dc.subjectobesityen_US
dc.subjecttestosteroneen_US
dc.titleEffects of androgens on glucose metabolism.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBest Practice & Research. Clinical Endocrinology & Metabolismen_US
dc.identifier.affiliationEndocrinologyen_US
dc.identifier.affiliationGeneral Medicineen_US
dc.identifier.affiliationEndocrine and Metabolic Health Unit, Royal Adelaide Hospital, South Australian Health and Medical Research Institute.en_US
dc.identifier.affiliationSchool of Medicine, University of Adelaide, South Australiaen_US
dc.identifier.affiliationFreemasons Centre for Male Health and Wellbeing, South Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35410798/en_US
dc.identifier.doi10.1016/j.beem.2022.101654en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-8261-3457en_US
dc.identifier.pubmedid35410798-
local.name.researcherGrossmann, Mathis
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

16
checked on Nov 1, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.